Get the Stockscreener App
0.00
100.00%
-2.0301
Mural Oncology Plc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$2.0301
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$35.38M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
0.00 | 35.38M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
Net debt of Mural Oncology Plc – LS:A3EE4M - TradingView — Track All Markets
Will Mural Oncology plc stock benefit from automation2026 world cup usa national team semifinals goalkeepers pressing system group prediction breakdown - ulpravda.ru
Return on invested capital % of Mural Oncology Plc – BER:IELK2BOB - TradingView — Track All Markets
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab - marketscreener.com
Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan
Net margin % of Mural Oncology Plc – BER:IELK2BOB - TradingView — Track All Markets
Current ratio of Mural Oncology Plc – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Earnings and Revenue – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Statistics – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Cash Flow – BER:IELK2BOB - TradingView — Track All Markets
MURA SEC FilingsMural Oncology PLC 10-K, 10-Q, 8-K Forms - Stock Titan
Mural Oncology Plc Balance Sheet – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Dividends – BER:IELK2BOB - TradingView — Track All Markets
Entry Recap: How Mural Oncology plc stock reacts to oil prices2025 Pullback Review & Weekly Sector Rotation Insights - Улправда
Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus Price Target from Brokerages - Defense World
How Mural Oncology plc stock reacts to oil pricesJuly 2025 Weekly Recap & Weekly High Potential Stock Alerts - Улправда
Market Recap: Will Mural Oncology plc stock benefit from automationJuly 2025 Review & Real-Time Stock Movement Alerts - Улправда
Will Mural Oncology plc stock outperform value stocksQuarterly Portfolio Report & High Return Trade Guides - Улправда
Will Mural Oncology plc stock outperform Nasdaq indexJuly 2025 WrapUp & Weekly Stock Breakout Alerts - DonanımHaber
Is Mural Oncology plc stock positioned for digital transformationJuly 2025 Volume & Low Drawdown Investment Strategies - DonanımHaber
Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals
Xoma Navigates Clinical Setback with Strategic Acquisition - AD HOC NEWS
Xoma completes acquisition of Mural Oncology - MSN
Acorn Capital Advisors LLC Reduces Position in Mural Oncology PLC $MURA - Defense World
Mural Oncology shareholders approve acquisition by XRA 5 Corp. - MSN
Xoma Royalty Expands Portfolio Through Mural Oncology Acquisition - AD HOC NEWS
Mural Oncology Announces Sanction of the Scheme by the High Court - 富途牛牛
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria
Xoma Completes Acquisition of Mural Oncology - TipRanks
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition - Research Tree
Xoma Royalty announces closing of transaction to acquire Mural Oncology plc - marketscreener.com
XOMA Royalty Corporation Completes Acquisition of Mural Oncology plc Under Irish High Court Sanctioned Scheme - Quiver Quantitative
Mural Oncology Plc Completes Acquisition by XRA 5 Corp. - TipRanks
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc - Yahoo Finance
XOMA Royalty completes acquisition of Mural Oncology - Investing.com India
Mural Oncology plc Announces Effective Date of Scheme Arrangement for Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) scheme with XOMA unit effective as Nasdaq listing ends - Stock Titan
Mural Oncology plc(NasdaqGM: MURA) dropped from S&P TMI Index - marketscreener.com
Mural Oncology plc (MURA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Mural Oncology plc(NasdaqGM: MURA) dropped from NASDAQ Composite Index - marketscreener.com
REGCitadel Group Mural Oncology PLCForm 8.3Mural Oncology plc - TradingView — Track All Markets
XOMA Royalty Corporation completed the acquisition of Mural Oncology plc from group of shareholders. - marketscreener.com
Irish court approves XOMA Royalty’s acquisition of Mural Oncology - Investing.com India
Irish court approves XOMA Royalty’s acquisition of Mural Oncology By Investing.com - Investing.com Australia
Mural Oncology plc Announces Court Approval of Scheme for Acquisition by XOMA Royalty Corporation's Subsidiary - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) wins Irish court nod for XOMA deal, Nasdaq trading expected to end Dec. 4 - Stock Titan
Mural Oncology (MURA) Stock Analysis Report | Financials & Insights - Benzinga
Irish takeover panel lists three companies in offer periods By Investing.com - Investing.com Nigeria
Mural Oncology Shareholders To Receive $2.035 Cash Per Share In XOMA Royalty Acquisition - Nasdaq
Can Mural Oncology plc stock sustain revenue growth2025 Biggest Moves & Safe Entry Zone Identification - moha.gov.vn
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):